042520 — HANS BIOMED Share Price
0.000.00%
Last trade - 00:00- KR₩168bn
- KR₩190bn
- KR₩78bn
- 41
- 21
- 30
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.24 | ||
| PEG Ratio (f) | 0.07 | ||
| EPS Growth (f) | 1,378.2% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.31 | ||
| Price to Tang. Book | 2.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.14 | ||
| EV to EBITDA | 186.02 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.83% | ||
| Return on Equity | -33.38% | ||
| Operating Margin | -4.81% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 66,990.99 | 80,098.46 | 59,098.03 | 74,459 | 78,032.04 | 124,000 | 150,500 | 8.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +38.32 | n/a | n/a | n/a | n/a | n/a | +24.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HansBiomed Co.,Ltd is a Korea-based company engaged in the biotechnology industry. The Company mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.
Directors
- Ho Chan Hwang CEO (57)
- Seok Bae Oh CFO (41)
- Won Gyun Gwon OTH (58)
- Geun Yeong Kim OTH (51)
- Yong Seok Cho DRC (49)
- Seong Hyeon Jeon DRC (39)
- Gye Won Kang DRC (78)
- Jin Kim DRC (51)
- Tae Jun Kim DRC (43)
- Jun Seok Park DRC (44)
- Seong Cheol Park DRC (52)
- Seong Eun Park DRC (42)
- Hong Yeol Yim DRC (43)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 15th, 1999
- Public Since
- October 9th, 2009
- No. of Shareholders
- 17,231
- No. of Employees
- 105
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 12,986,979
- Address
- 7, Jeongui-ro 8-gil, Songpa-gu, SEOUL, 05836
- Web
- http://hansbiomed.com/
- Phone
- +82 24662266
- Auditors
- Hanmi Accounting
Upcoming Events for 042520
Q3 2024 Hans Biomed Corp Earnings Release
Similar to 042520
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
FAQ
What is the HANS BIOMED share price?
As of Today at 19:10 UTC, shares in HANS BIOMED are trading at KR₩12,900. This share price information is delayed by 15 minutes.
How has the HANS BIOMED share price performed this year?
Shares in HANS BIOMED last closed at KR₩12,900 and the price had moved by -10.92% over the past 365 days. In terms of relative price strength the HANS BIOMED share price has underperformed the FTSE Developed Asia Pacific Index by -10.83% over the past year.
What are the analyst and broker recommendations for HANS BIOMED?
The overall consensus recommendation for HANS BIOMED is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the HANS BIOMED dividend yield?
HANS BIOMED does not currently pay a dividend.
Does HANS BIOMED pay a dividend?
HANS BIOMED does not currently pay a dividend.
When does HANS BIOMED next pay dividends?
HANS BIOMED does not currently pay a dividend.
How do I buy HANS BIOMED shares?
To buy shares in HANS BIOMED you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of HANS BIOMED?
As of the previous close price of KR₩12,900, shares in HANS BIOMED had a market capitalisation of KR₩168bn.
Where are HANS BIOMED shares listed?
Here are the trading details for HANS BIOMED:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 042520
What kind of share is HANS BIOMED?
Based on an overall assessment of its quality, value and momentum HANS BIOMED is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a HANS BIOMED share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the HANS BIOMED share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HANS BIOMED. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.09%.
As of the last closing price of KR₩12,900, shares in HANS BIOMED were trading -22.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the HANS BIOMED PE Ratio?
The HANS BIOMED PE ratio based on its reported earnings over the past 12 months is 6.24. The shares last closed at KR₩12,900.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of HANS BIOMED?
HANS BIOMED's management team is headed by:
- Ho Chan Hwang - CEO
- Seok Bae Oh - CFO
- Won Gyun Gwon - OTH
- Geun Yeong Kim - OTH
- Yong Seok Cho - DRC
- Seong Hyeon Jeon - DRC
- Gye Won Kang - DRC
- Jin Kim - DRC
- Tae Jun Kim - DRC
- Jun Seok Park - DRC
- Seong Cheol Park - DRC
- Seong Eun Park - DRC
- Hong Yeol Yim - DRC